Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL365995 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL7306062 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL1162598 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL670258 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL582331 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL420405 | 0.98 | ALDH1A1 (0.57) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL28195321 | 0.96 | ALDH1A1 (0.52) | ALDH1A1LMNAF2TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL29837305 | 0.96 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| SCHEMBL6665458 | 0.96 | ALDH1A1 (0.55) | ALDH1A1LMNAF2TSHRTDP1 | |
| Water SCHEMBL27446036 | 0.94 | ALDH1A1 (0.50) | ALDH1A1LMNAF2TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | claimed |
| WO-2020067683-A1 | NOVEL PROCESS FOR THE PREPARATION OF (+)-CIBENZOLINE SUCCINATE | CELLTRION INC. (KR) | 2020-04-02 | — | — | WO | claimed |
| US-8198316-B2 | Process for the preparation of 5,6 -dihydro -4H-4(S)-ethylamino-6(S)-methylthieno[2,3-b] thiopyran-2-sulfonamide- 7,7 -dioxide and its salt | FDC LTD (IN) | 2012-06-12 | — | — | US | claimed |
| US-20090264662-A1 | PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC LTD (IN) | 2009-10-22 | — | — | US | claimed |
| EP-1765828-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC LTD (IN) | 2007-12-05 | — | — | EP | claimed |
| EP-1765828-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC Limited (IN) | 2007-03-28 | — | — | EP | claimed |
| WO-2006038222-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC LTD (IN) | 2006-04-13 | — | — | WO | claimed |
| EP-3210965-B2 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-3868739-B1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | Grünenthal GmbH (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| EP-3210965-B1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | GRUENENTHAL GMBH (DE) | 2021-11-17 | — | — | EP | disclosed |
| WO-2008012047-A1 | PROCESS FOR THE PREPARATION OF (1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2008-01-31 | — | — | WO | disclosed |
| EP-1765828-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| EP-1765828-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC Limited (IN) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006038222-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | FDC LTD (IN) | 2006-04-13 | — | — | WO | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-5457224-A | Resolution of racemic verapamil | KNOLL AKTIENGESELLSCHAFT (DE) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739049-B2 | Process for the preparation of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | COMT, CYP1A1, CYP2E1 | SLC6A2 3218/4885SLC6A3 2351/4885ADRB2 314/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | SLC6A2 1755/4885SLC6A3 2182/4885ADRB2 1861/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | SLC6A2 1185/4885SLC6A3 2507/4885ADRB2 540/4885 |
| US-20090264662-A1 | PROCESS FOR THE PREPARATION OF 5,6 -DIHYDRO -4H-4(S)-ETHYLAMINO-6(S)-METHYLTHIENO[2,3-b] THIOPYRAN-2-SULFONAMIDE- 7,7 -DIOXIDE AND ITS SALT | DHODH, SPR, TST | SLC6A2 1096/4885SLC6A3 556/4885ADRB2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.